The age requirement for taking Wegovy: what the licence actually says

The misconception worth clearing up first

A lot of people arrive at this question assuming Wegovy has a specific age window — say, 18 to 65 — beyond which it either isn't suitable or isn't available. That isn't how the UK licence works. The NHS medicines page for semaglutide confirms the medicine is authorised for adults, which in UK law means 18 and over, with no stated upper bound. The idea of an upper age limit is understandable (many medicines carry warnings about use in older adults) but for Wegovy the licence itself does not draw that line. What it does require is a proper clinical assessment, which naturally becomes more detailed the more complex someone's medical history is. Age matters in that context; it just isn't a hard cut-off.

It's a distinction worth making clearly, because the misconception can put people off asking at all.

Under 18: why the licence draws the line there

Wegovy is not authorised for anyone under 18 in the UK for weight management. This isn't simply a cautious default. Clinical trials supporting the UK licence studied adults, meaning there is limited safety and efficacy data for younger age groups in this specific context. Prescribing a medicine outside its licensed age range is possible in some clinical settings (known as off-label use) but that is a specialist decision made in exceptional circumstances, not something a private weight-management service would do. If a teenager or young person is concerned about their weight, the right route is a conversation with their GP, who can refer them to appropriate NHS services. You can read more about how Wegovy works as a treatment to understand the context better.

For anyone under 18 reading this: the medicine genuinely isn't the right tool yet, and there are other evidence-based pathways through the NHS.

Older adults: what prescribers look at more carefully

There is no age at which Wegovy becomes automatically off-limits. People in their 60s, 70s and beyond have been included in clinical research for GLP-1 medicines, and weight management remains clinically relevant well into later life given its links to cardiovascular risk, joint health and metabolic conditions. That said, a prescriber will look more carefully at a few things when someone is older. Kidney function matters, because GI side effects like vomiting or diarrhoea carry a greater dehydration risk if the kidneys are already under strain. Polypharmacy (taking several medicines simultaneously) is more common in older adults, and a prescriber will want to map any interactions. Swallowing difficulties or reduced appetite unrelated to weight management would also be relevant. Our clinical team reviews every consultation individually, so these factors are worked through case by case rather than against a blunt age rule. The NICE appraisal of semaglutide (TA875) does not set an upper age threshold either, though it does specify that treatment should be delivered alongside appropriate support.

BMI, age, and the full eligibility picture

Meeting the age requirement is the starting point, not the whole answer. Wegovy's UK licence requires a BMI of at least 30, or at least 27 alongside a weight-related condition such as high blood pressure, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. Age sits alongside these criteria rather than overriding them: a 19-year-old with a BMI of 25 and no qualifying condition would not be eligible; a 72-year-old with a BMI of 33 and hypertension might well be, subject to the prescriber's full assessment. If you're curious about how long Wegovy has been available and the timeline of its development, that context can help explain why the evidence base looks the way it does. If you want to understand what private treatment costs alongside these eligibility points, the Wegovy cost page sets out what's typically involved. For the practical side of how the injection is used once someone is approved, the administration guide covers the key steps. Questions about semaglutide more broadly (its mechanism, history, and how it compares with other options) are covered on the semaglutide overview page. Recent regulatory updates, including the approval of the 7.2mg pen and the oral tablet, are tracked on the Wegovy updates page.

If you are 18 or over and want to find out whether you are clinically suitable, a free consultation with a GPhC-registered prescriber at nume is the straightforward next step.

Start your free consultation and a prescriber will review your details the same day.